Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BHARAT BIOTECH INTERNATIONAL LIMITED has two pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by two examiners but remain within one art unit, indicating examiner-level distribution inside a common technical examination setting. ALLEN, MICHAEL D is the busiest examiner, with one pending matter.
Counsel can use the shared art-unit context to coordinate technical positions while treating each examiner’s action independently. The profile does not support assuming identical examination treatment, because the matters involve separate examiners. A consistent portfolio position should therefore be paired with response strategies tailored to each pending biotechnology and pharmaceutical matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294775 | SYNERGISM OF IMMUNOGENICITY VIA COMBINED PARENTERAL AND MUCOSAL IMMUNIZATION AGAINST COVID-19 | ALLEN, MICHAEL D | — |
| 18565210 | ADJUVANTED INACTIVATED RECOMBINANT RABIES VIRUS VECTORED CORONAVIRUS VACCINE FORMULATIONS | ZOU, NIANXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294775 | SYNERGISM OF IMMUNOGENICITY VIA COMBINED PARENTERAL AND MUCOSAL IMMUNIZATION AGAINST COVID-19 | ALLEN, MICHAEL D | — |
| 18565210 | ADJUVANTED INACTIVATED RECOMBINANT RABIES VIRUS VECTORED CORONAVIRUS VACCINE FORMULATIONS | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294775 | SYNERGISM OF IMMUNOGENICITY VIA COMBINED PARENTERAL AND MUCOSAL IMMUNIZATION AGAINST COVID-19 | ALLEN, MICHAEL D | 1671 | §102§103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18565210 | ADJUVANTED INACTIVATED RECOMBINANT RABIES VIRUS VECTORED CORONAVIRUS VACCINE FORMULATIONS | ZOU, NIANXIANG | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBHARAT BIOTECH INTERNATIONAL LIMITED has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Michael D Allen has the most, with 1 of BHARAT BIOTECH INTERNATIONAL LIMITED's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
